Oppenheimer Maintains Outperform on Trevi Therapeutics, Raises Price Target to $24
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $23 to $24.
Oppenheimer analyst Leland Gershell maintains Trevi Therapeutics (NASDAQ:TRVI) with a Outperform and raises the price target from $23 to $24.